Mediolanum International Funds Ltd Has $10.13 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Mediolanum International Funds Ltd reduced its holdings in DexCom, Inc. by 2.4%, selling 3,633 shares and now owning 149,593 shares valued at approximately $10.13 million.
• DexCom's stock price opened at $88.99, with a market capitalization of $34.89 billion, and has seen a yearly range between $57.52 and $93.25.
• Several analysts have **mixed** ratings on DexCom, with most recent targets ranging from $90.00 to $106.00, leading to a consensus rating of **"Moderate Buy."**

Mediolanum International Funds Ltd decreased its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 149,593 shares of the medical device company's stock after selling 3,633 shares during the period. Mediolanum International Funds Ltd's holdings in DexCom were worth $10,133,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in DXCM. Golden State Wealth Management LLC lifted its stake in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares during the last quarter. Optiver Holding B.V. purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $33,000. Heck Capital Advisors LLC purchased a new stake in shares of DexCom in the 4th quarter valued at approximately $38,000. Alpine Bank Wealth Management acquired a new position in shares of DexCom in the first quarter worth $40,000. Finally, Private Trust Co. NA increased its position in DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after purchasing an additional 335 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on DXCM shares. The Goldman Sachs Group started coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price target on the stock. Mizuho raised their target price on shares of DexCom from $95.00 to $100.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Truist Financial began coverage on shares of DexCom in a research report on Monday, June 16th. They issued a "buy" rating and a $102.00 price target on the stock. Robert W. Baird decreased their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Finally, Piper Sandler reduced their price objective on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $99.00.

Insider Activity

In other news, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the transaction, the executive vice president owned 109,621 shares in the company, valued at $9,329,843.31. This represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of the company's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director owned 33,411 shares of the company's stock, valued at $2,766,430.80. This trade represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 28,656 shares of company stock worth $2,412,191 in the last ninety days. Company insiders own 0.32% of the company's stock.

DexCom Trading Up 0.4%

Shares of DXCM traded up $0.37 on Wednesday, reaching $89.72. 1,186,101 shares of the company's stock were exchanged, compared to its average volume of 3,816,643. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $35.18 billion, a P/E ratio of 67.04, a price-to-earnings-growth ratio of 1.91 and a beta of 1.44. The business has a 50 day moving average price of $84.67 and a two-hundred day moving average price of $80.56. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The company's quarterly revenue was up 12.5% on a year-over-year basis. During the same period last year, the firm earned $0.32 earnings per share. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.